
March 11 (Reuters) - Gilead Sciences Inc GILD.O:
GILEAD SCIENCES PRESENTS FIRST CLINICAL DATA FOR INVESTIGATIONAL ONCE-YEARLY LENACAPAVIR FOR HIV PREVENTION
GILEAD SCIENCES: DATA SHOWS PROMISING ONCE-YEARLY LENACAPAVIR FOR PREP PHARMACOKINETIC PROFILES OVER 52 WEEKS
GILEAD SCIENCES: SAFETY DATA SHOWED BOTH FORMULATIONS OF ONCE-YEARLY LENACAPAVIR FOR PREP WERE WELL TOLERATED, WITH NO NEW SAFETY SIGNALS
GILEAD SCIENCES: NEW PREP MODALITY PREFERENCE DATA SHOWS PREFERENCE FOR TWICE-YEARLY LENACAPAVIR VERSUS ONCE DAILY ORALS IN PURPOSE 1 SURVEY PARTICIPANTS
GILEAD SCIENCES: NEW STUDY POPULATION DATA FROM PURPOSE 1 SHOW COMPARABLE PHARMACOKINETIC & SAFETY PROFILES FOR ADOLESCENT & ADULT TRIAL PARTICIPANTS
Source text: [ID:]